BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36951579)

  • 1. Impact of skeletal muscle volume on patients with BCLC stage-B hepatocellular carcinoma undergoing sorafenib therapy.
    Saeki I; Yamasaki T; Yamauchi Y; Kawaoka T; Uchikawa S; Hiramatsu A; Aikata H; Kobayashi K; Kondo T; Ogasawara S; Chiba T; Kawano R; Chayama K; Kato N; Takami T
    Cancer Med; 2023 May; 12(9):10625-10635. PubMed ID: 36951579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
    Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
    Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Inghilesi AL; Gallori D; Antonuzzo L; Forte P; Tomcikova D; Arena U; Colagrande S; Pradella S; Fani B; Gianni E; Boni L; Laffi G; Di Costanzo F; Marra F
    World J Gastroenterol; 2014 Jan; 20(3):786-94. PubMed ID: 24574751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma.
    Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Park MS; Kim EH; Seong J; Lee DY; Han KH
    Liver Int; 2012 Aug; 32(7):1120-7. PubMed ID: 22524688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice.
    Lee IC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lin HC; Lee FY; Huang YH
    Medicine (Baltimore); 2015 Apr; 94(14):e688. PubMed ID: 25860213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Pinter M; Sieghart W; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Matejka J; Stauber R; Buder R; Grünberger B; Schöniger-Hekele M; Müller C; Peck-Radosavljevic M
    Aliment Pharmacol Ther; 2011 Oct; 34(8):949-59. PubMed ID: 21883324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.
    Lee PC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lee MH; Hou MC; Lee FY; Lin HC; Huang YH
    Liver Int; 2018 Feb; 38(2):321-330. PubMed ID: 28736952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: A study on prognostic factors of the viral and tumor status.
    Lee SW; Lee TY; Peng YC; Yang SS; Yeh HZ; Chang CS
    Medicine (Baltimore); 2019 Nov; 98(44):e17692. PubMed ID: 31689794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
    Piñero F; Marciano S; Fernández N; Silva J; Anders M; Zerega A; Ridruejo E; Romero G; Ameigeiras B; D'Amico C; Gaite L; Bermúdez C; Reggiardo V; Colombato L; Gadano A; Silva M
    World J Gastroenterol; 2019 Jul; 25(27):3607-3618. PubMed ID: 31367160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Xu L; Gao H; Huang J; Wang H; Zhou Z; Zhang Y; Li S; Chen M
    J Gastroenterol Hepatol; 2015 Jun; 30(6):1032-9. PubMed ID: 25639513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
    World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Chen L; Su H; Shao H; Xu K; Liang S; Liu J
    Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread.
    Sinn DH; Cho JY; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    PLoS One; 2015; 10(4):e0124434. PubMed ID: 25923439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma.
    Liu KC; Hao YH; Lv WF; Jia WD; Ji CS; Zhou CZ; Cheng DL; Xu SB; Gao ZG; Su MX; Shi CS
    Drug Des Devel Ther; 2020; 14():3461-3468. PubMed ID: 32904650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of radiotherapy in Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma treated with sorafenib.
    Chang WI; Kim BH; Kim YJ; Yoon JH; Jung YJ; Chie EK
    J Gastroenterol Hepatol; 2022 Feb; 37(2):387-394. PubMed ID: 34693560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure.
    Cheng TY; Lee PC; Chen YT; Chao Y; Hou MC; Huang YH
    Sci Rep; 2020 Oct; 10(1):18375. PubMed ID: 33110117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma.
    Saeki I; Yamasaki T; Yamauchi Y; Takami T; Kawaoka T; Uchikawa S; Hiramatsu A; Aikata H; Kawano R; Kobayashi K; Kondo T; Ogasawara S; Chiba T; Chayama K; Kato N; Sakaida I
    Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34067075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined measurements of tumor number and size helps estimate the outcome of resection of Barcelona clinic liver cancer stage B hepatocellular carcinoma.
    Wang X; Wang Z; Wu L
    BMC Surg; 2016 Apr; 16():22. PubMed ID: 27094483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.